Mohan, thanks for some insight on CNTO, they appear cheap on a valuation basis for a biotech company
I think that Cnto's Reopro anti-clotting treatment is a super high growth business, I was at the ST Lukes medical center, visiting a friend getting a stent last month and it is a dramtic growth industry.
The demographics will only enhance this trend going forward. A get together with one of the top stent companies such as GDT, or BSX, or
one of the others would yield synergies I'm sure.
'm hearing there is a smattering of takeout rumors on the Street, and there also
have been rumors...about a potential co-promotion deal" to team Centocor's
anti-clotting treatment ReoPro with a stent manufacturer, said Robert Toth,
biotechnology analyst, Vector Securities International.
"We also believe the
company's cardiovascular franchise is second to none. "Expectations, in general, appear
extremely low, making Centocor, in our view, the most undervalued top-tier biotech
stock," said Silverman. "Despite lowering our estimates, our confidence in Remicade
growth is higher than ever, with what is ostensibly the worst quarter out of the way,
higher projected growth than its peers' and the stock trading at a meaningful discount to
the top-tier biotech group." "
there is alot to be said for the bullish observations. imo
I see cnto is moving up to the 45 resistance, I would expect it to be able to take that level out and challenge the old high at 53-54 $
a move above the old highs would be very bullish indeed. |
